Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice
BackgroundIt is presently unclear what clinical pathways are followed for patients with non-metastatic PDAC in specialised centres for pancreatic surgery across the United Kingdom (UK).MethodsBetween August 2019 and August 2020 an electronic survey was conducted aiming at a national cohort of pancre...
Main Authors: | Georgios Gemenetzis, Siobhan McKay, Samir Pathak, John Moir, Richard Laing, Nigel B. Jamieson, Alastair L. Young, Nikolaos A. Chatzizacharias, Francesco Giovinazzo, Keith J. Roberts |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.791946/full |
Similar Items
-
Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study
by: Jie Yang, et al.
Published: (2024-04-01) -
New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy
by: Sofia Dallavalle, et al.
Published: (2024-06-01) -
Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
by: Fuyuhiko Motoi, et al.
Published: (2020-03-01) -
Advantages and advances in neoadjuvant therapy of pancreatic cancer
by: HU Binwei, SHEN Baiyong
Published: (2024-01-01) -
Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)